Total Payments
$25,651
2024 Payments
$3,236
Companies
79
Transactions
1,338
Medicare Patients
34,649
Medicare Billing
$16.2M
Payment Breakdown by Category
Food & Beverage$24,392 (95.1%)
Consulting$750.00 (2.9%)
Education$508.41 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $24,392 | 1,318 | 95.1% |
| Consulting Fee | $750.00 | 1 | 2.9% |
| Education | $508.41 | 19 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $2,748 | 152 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,627 | 184 | $0 (2024) |
| Amgen Inc. | $1,982 | 100 | $0 (2023) |
| ABBVIE INC. | $1,364 | 30 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,170 | 77 | $0 (2024) |
| Seagen Inc. | $1,114 | 56 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,091 | 62 | $0 (2024) |
| Janssen Biotech, Inc. | $1,087 | 63 | $0 (2024) |
| Celgene Corporation | $1,052 | 65 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $929.49 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,236 | 149 | E.R. Squibb & Sons, L.L.C. ($258.84) |
| 2023 | $3,196 | 172 | Seagen Inc. ($353.44) |
| 2022 | $2,787 | 150 | Amgen Inc. ($238.29) |
| 2021 | $4,562 | 180 | AbbVie Inc. ($819.48) |
| 2020 | $2,738 | 138 | Genentech USA, Inc. ($368.67) |
| 2019 | $3,230 | 163 | Genentech USA, Inc. ($610.77) |
| 2018 | $2,989 | 175 | Genentech USA, Inc. ($490.75) |
| 2017 | $2,913 | 211 | Genentech USA, Inc. ($705.94) |
All Payment Transactions
1,338 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.56 | General |
| 12/23/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: BioOncology | ||||||
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Oncology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $8.82 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Tecentriq Hybreza (Biological) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: BioOncology | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.80 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $3.99 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $0.70 | General |
| Category: Hematology | ||||||
| 12/10/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.07 | General |
| Category: Hematology | ||||||
| 11/27/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Genentech USA, Inc. | Itovebi (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: BioOncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Oncology | ||||||
| 11/19/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $28.17 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.90 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 81 | 10,208 | 292,457 | $16.3M | $4.7M |
| 2022 | 75 | 9,450 | 295,403 | $14.0M | $3.9M |
| 2021 | 72 | 7,883 | 378,582 | $12.1M | $3.3M |
| 2020 | 77 | 7,108 | 397,161 | $14.1M | $4.3M |
Total Patients
34,649
Total Services
1,363,603
Medicare Billing
$16.2M
Procedure Codes
305
All Medicare Procedures & Services
305 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 22,400 | $2.5M | $970,266 | 39.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 31,080 | $1.6M | $736,512 | 44.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 142 | 28,980 | $1.2M | $535,652 | 44.2% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 13,680 | $2.0M | $521,387 | 25.8% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 20 | 13,510 | $1.5M | $482,626 | 32.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 129 | 16,900 | $1.0M | $281,441 | 27.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 40 | 1,524 | $1.3M | $131,295 | 10.4% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 14 | 5,148 | $257,400 | $128,944 | 50.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 648 | 1,320 | $330,000 | $116,648 | 35.3% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 11 | 2,730 | $600,600 | $94,561 | 15.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 144 | 945 | $457,380 | $88,744 | 19.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 27 | 33,500 | $351,750 | $77,897 | 22.1% |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | Office | 2023 | 13 | 444 | $399,600 | $64,787 | 16.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 169 | 271 | $93,495 | $35,308 | 37.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 29 | 236 | $165,200 | $31,503 | 19.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 910 | 2,767 | $207,525 | $28,605 | 13.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 40 | 20,670 | $96,322 | $27,351 | 28.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 948 | 3,460 | $259,500 | $26,213 | 10.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 915 | 3,046 | $91,380 | $25,418 | 27.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 200 | 499 | $64,870 | $22,949 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 285 | 333 | $58,275 | $18,741 | 32.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 312 | 1,615 | $121,125 | $16,330 | 13.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 112 | 742 | $133,560 | $15,704 | 11.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 96 | 96 | $47,520 | $14,932 | 31.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 27 | 36,720 | $110,160 | $14,101 | 12.8% |
About Dr. Mitchell Martin, MD
Dr. Mitchell Martin, MD is a Hematology & Oncology healthcare provider based in Powell, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639179708.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Martin, MD has received a total of $25,651 in payments from pharmaceutical and medical device companies, with $3,236 received in 2024. These payments were reported across 1,338 transactions from 79 companies. The most common payment nature is "Food and Beverage" ($24,392).
As a Medicare-enrolled provider, Martin has provided services to 34,649 Medicare beneficiaries, totaling 1,363,603 services with total Medicare billing of $16.2M. Data is available for 4 years (2020–2023), covering 305 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Powell, TN
- Active Since 07/29/2005
- Last Updated 04/09/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1639179708
Products in Payments
- OPDIVO (Biological) $2,124
- VENCLEXTA (Drug) $1,129
- KEYTRUDA (Biological) $965.78
- LIBTAYO (Biological) $562.44
- Lenvima (Drug) $501.44
- Avastin (Biological) $486.74
- ADCETRIS (Biological) $484.59
- DARZALEX (Biological) $484.28
- TUKYSA (Drug) $472.35
- JAKAFI (Drug) $455.71
- TECENTRIQ (Biological) $441.44
- Revlimid (Drug) $390.35
- KISQALI (Drug) $375.94
- Perjeta (Biological) $365.56
- ZEJULA (Drug) $364.06
- PADCEV (Biological) $363.24
- SARCLISA (Biological) $355.08
- Neulasta (Biological) $351.61
- ERLEADA (Drug) $332.34
- Kyprolis (Biological) $310.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.